Combination of Plasma Rich in Growth Factors With Topical 4% Hydroquinone Compared With Topical 4% Hydroquinone Alone in the Treatment of Dermal Type of Melasma: A Single-Blinded Randomized Split-Face Study.

Background: Response to the current available treatments of melasma, dermal type, in particular, is usually gradual and can result in possible side effects.

Aim And Objectives: In this study, we aim to evaluate the efficacy of the combination of plasma rich in growth factors (PRGF) and topical 4% hydroquinone (HQ) in comparison with monotherapy using topical 4% HQ alone in the treatment of dermal type of melasma.

Materials And Methods: This is a single-blinded, randomized, split-face clinical trial on twenty female patients with dermal type of melasma.